AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
COVID-19 and breast cancer: How should we treat our patients?
Reducing damage to swallowing muscles during radiotherapy for head and neck cancers
Comment: JAVELIN-100 for metastatic urothelial cancer
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma
Updated results from KEYNOTE-426 for metastatic kidney cancer
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer
PARP inhibitors in prostate cancer: Choices of tests and how to test?